Heart Failure

Heart Failure - 2017 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/244042

Contents of this Issue

Navigation

Page 2 of 61

3 HFr EF • The definition of HFrEF has been variable, but to date efficacious therapies have been demonstrated only in patients with an EF of ≤35% or ≤40%. • Approximately half of patients with HFrEF may also have variable degrees of LV enlargement. • Although coronary artery disease (CAD) with antecedent myocardial infarction (MI) is a major cause of HFrEF, many other risk factors may lead to LV enlargement and HFrEF. HFp EF • In patients with clinical HF, studies estimate that the prevalence of HFpEF ranges from 40% to 71% because the EF cutoff has varied between >40% and ≥55%. • Proposed criteria to define HFpEF include: ▶ Clinical signs or symptoms of HF ▶ Evidence of preserved or normal left ventricular ejection fraction (LVEF) and ▶ Evidence of abnormal LV diastolic dysfunction that can be determined by Doppler echocardiography or cardiac catheterization. • Prevalent associated conditions include: ▶ Hypertension (60%–89%) ▶ Older age, female ▶ Obesity ▶ CAD ▶ Diabetes mellitus ▶ Atrial fibrillation (AF) ▶ Hyperlipidemia

Articles in this issue

view archives of Heart Failure - Heart Failure - 2017 Update